Last reviewed · How we verify
Inhaled Fluticasone Propionate
Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory cytokine production.
Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory cytokine production. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Inhaled Fluticasone Propionate |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | Inhaled corticosteroid (ICS) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
When inhaled, fluticasone propionate acts locally in the lungs to inhibit the release of inflammatory mediators from immune cells, reduce mucus production, and decrease airway edema. This anti-inflammatory action reduces airway hyperresponsiveness and improves airflow in obstructive airway diseases. The inhaled route delivers the drug directly to the site of inflammation while minimizing systemic exposure.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia/hoarseness
- Tremor
- Headache
- Nervousness/anxiety
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers (PHASE4)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled Fluticasone Propionate CI brief — competitive landscape report
- Inhaled Fluticasone Propionate updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI